EGFR and neoplasm: Compared to PBS-treated animals, JNJ-61186372-LF and EGFR-LF monovalent antibodies showed significant percent tumor growth inhibition (% TGI) of 79 and 81, respectively (each with p < 0.05) (Fig. 4C).